109 related articles for article (PubMed ID: 21823168)
1. Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia.
Suzuki Y; Ono S; Sugai T; Fukui N; Watanabe J; Tsuneyama N; Sawamura K; Someya T
Hum Psychopharmacol; 2011 Aug; 26(6):440-3. PubMed ID: 21823168
[TBL] [Abstract][Full Text] [Related]
2. Changes in PR and QTc intervals after switching from olanzapine to risperidone in patients with stable schizophrenia.
Suzuki Y; Sugai T; Ono S; Sawamura K; Fukui N; Watanabe J; Tsuneyama N; Saito M; Someya T
Psychiatry Clin Neurosci; 2014 May; 68(5):353-6. PubMed ID: 24405493
[TBL] [Abstract][Full Text] [Related]
3. Effects of olanzapine on resting heart rate in Japanese patients with schizophrenia.
Tajiri M; Suzuki Y; Sugai T; Tsuneyama N; Someya T
PLoS One; 2018; 13(7):e0199922. PubMed ID: 30016331
[TBL] [Abstract][Full Text] [Related]
4. "Long-acting" olanzapine in maintenance therapy of schizophrenia: A study with plasma levels.
Mauri MC; Maffini M; Di Pace C; Reggiori A; Paletta S; Moliterno D; Rovera C; Altamura CA
Int J Psychiatry Clin Pract; 2015 Jun; 19(2):99-105. PubMed ID: 25547438
[TBL] [Abstract][Full Text] [Related]
5. Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia.
Suzuki Y; Sugai T; Fukui N; Watanabe J; Ono S; Tsuneyama N; Saito M; Someya T
Hum Psychopharmacol; 2013 May; 28(3):215-9. PubMed ID: 23553637
[TBL] [Abstract][Full Text] [Related]
6. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
Beasley CM; Tollefson G; Tran P; Satterlee W; Sanger T; Hamilton S
Neuropsychopharmacology; 1996 Feb; 14(2):111-23. PubMed ID: 8822534
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
[TBL] [Abstract][Full Text] [Related]
8. Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics.
Suzuki Y; Sugai T; Fukui N; Watanabe J; Ono S; Tsuneyama N; Saito M; Someya T
Schizophr Res; 2013 Apr; 145(1-3):116-9. PubMed ID: 23375624
[TBL] [Abstract][Full Text] [Related]
9. Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia.
Bushe C; Sniadecki J; Bradley AJ; Poole Hoffmann V
J Psychopharmacol; 2010 Jul; 24(7):1001-9. PubMed ID: 19240085
[TBL] [Abstract][Full Text] [Related]
10. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.
Kinon BJ; Volavka J; Stauffer V; Edwards SE; Liu-Seifert H; Chen L; Adams DH; Lindenmayer JP; McEvoy JP; Buckley PF; Lieberman JA; Meltzer HY; Wilson DR; Citrome L
J Clin Psychopharmacol; 2008 Aug; 28(4):392-400. PubMed ID: 18626265
[TBL] [Abstract][Full Text] [Related]
11. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
12. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
[TBL] [Abstract][Full Text] [Related]
13. Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia.
Tsuneyama N; Suzuki Y; Sawamura K; Sugai T; Fukui N; Watanabe J; Ono S; Saito M; Someya T
PLoS One; 2016; 11(3):e0149518. PubMed ID: 26930407
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome and olanzapine plasma levels in acute schizophrenia.
Mauri MC; Steinhilber CP; Marino R; Invernizzi E; Fiorentini A; Cerveri G; Baldi ML; Barale F
Eur Psychiatry; 2005 Jan; 20(1):55-60. PubMed ID: 15642445
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
Kinon BJ; Noordsy DL; Liu-Seifert H; Gulliver AH; Ascher-Svanum H; Kollack-Walker S
J Clin Psychopharmacol; 2006 Oct; 26(5):453-61. PubMed ID: 16974184
[TBL] [Abstract][Full Text] [Related]
16. Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor metabolic parameters in patients with schizophrenia.
Lu ML; Chen CH; Kuo PT; Lin CH; Wu TH
Schizophr Res; 2018 Mar; 193():139-145. PubMed ID: 28720417
[TBL] [Abstract][Full Text] [Related]
17. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.
Crawford AM; Beasley CM; Tollefson GD
Schizophr Res; 1997 Jul; 26(1):41-54. PubMed ID: 9376336
[TBL] [
